2Gratwohl A, Brand R, Apperley J, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) [ J ]. Haematologica, 2006,91 (4) :513-521.
4Nemecek E R, Gooley T A, Woolfrey A E, et al. Outcome of allogeneic bone marrow transplantation for children with advanced acute myeloid leukemia[ J]. Bone Marrow Transplant, 2004,34(9) :799-806.
1Arellano ML, Langston A, Winton E, et al. Treatment ofrelapsed acute leukemia after allogeneic transplantation.. A singlecenter experience. Biol Blood and Marrow Transplant, 2007,13(1):116-123.
2Introna M, Franceschetti M, Ciocca A, et al. Rapid and massiveexpansion of cord blood-derived cytokine-induced killer cells: Aninnovative proposal for the treatment of leukemia relapse aftercord blood transplantation. Bone Marrow Transplant, 2006, 38(9):621-627.
3GIuckman E, Broxmeyer HA, Auerbah AD, et al.Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engi J Med, 1989,321(17) :1174-1178.
4Gluckman E, Rocha V. Cord blood transplantation: state of the art. Haematologica, 2009,94(4) :451-454.
5Stanevsky A, Goldstein G, Nagler A. Umbilical cord blood transplantation: Pros, cons and beyond. Blood Rev, 2009,23 (5) : 199-204.
6Gratwohl A, Brand R, Apperley J, et al. Allogeneichematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, longterm data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation(EBMT). Haematologiea, 2006,91 (4) : 513-521.
7Verneris MR, Brunstein CG, Barker J, et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versusleukemia effect in recipients of 2 units. Blood, 2009, 114(19): 4293-4299.
8MacMillan ML, Davies SM, Nelson GO, et al. Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant, 2008, 14(9 Suppl):16-22.
9Verneris MR, Burke MJ. Novel approaches to prevent leukemia relapse following allogeneic hematopoietic cell transplantation. Curr Hematol Malig Rep, 2010,5(3):157-162.
10AldersonRF, Kreitman RJ, Chen T, et al. CAT-8015: a second-generation pseudomonas exotoxin A-based immuno- therapy targeting CD22-expressing hematologic malignancies. Clin Cancer Res, 2009, 15(3) :832-839.
